Honasa Consumer, the parent company of Mamaearth, is acquiring a 58% stake in Mumbai-based Fluence Pharma for ₹135 crore. The company is also launching a new subsidiary, Honasa Health, to expand into the nutraceuticals market. This deal marks a strategic push for the beauty-focused firm into science-led healthcare products.
What Happened
Honasa Consumer Ltd (HCL), the company behind brands like Mamaearth and The Derma Co, has announced the acquisition of a 58% equity stake in Fluence Pharma Private Ltd. The deal is valued at approximately ₹135 crore. This is a secondary purchase, meaning HCL is buying existing shares rather than injecting fresh capital into the company. The board also approved the formation of a wholly-owned subsidiary, Honasa Health Private Ltd, which will lead the company’s push into the consumer-facing (B2C) nutraceuticals business.
Strategic Pivot To Nutraceuticals
This acquisition represents a clear move by Honasa to diversify beyond its core beauty and personal care portfolio. Fluence Pharma specializes in condition-specific supplement kits, such as hair and skin-related treatments. Unlike Mamaearth’s mass-market retail approach, Fluence operates a doctor-led model, distributing products through a network of over 3,000 dermatologists. By acquiring this platform, Honasa is attempting to combine its marketing expertise with a science-backed, clinical product base. Fluence Pharma’s revenue has shown steady growth, rising from ₹32.24 crore in FY23 to ₹37.21 crore in FY25.
The New Subsidiary And B2C Focus
While Fluence Pharma currently focuses on doctor-led distribution, the newly incorporated subsidiary, Honasa Health, will focus on the B2C nutraceutical market. This suggests that HCL intends to take the science-led products currently sold through clinics and potentially package them for direct-to-consumer sales. The subsidiary will start with a nominal paid-up capital of ₹1,00,000. This structure allows Honasa to keep its established beauty business separate from its new health and wellness operations, which may have different regulatory and marketing requirements.
Risks And Sector Realities
Investors should note that the nutraceutical and supplement market in India is highly competitive. Large FMCG players and specialized pharmaceutical companies are already present in this segment. Unlike the beauty segment, where branding and influencer marketing drive sales, the nutraceutical business is subject to stricter regulatory oversight by bodies like the FSSAI. Ensuring product quality, maintaining clinical claims, and navigating health regulations are significant execution risks. Additionally, merging a doctor-led distribution model with a mass-market B2C model can often lead to operational challenges, especially if the company struggles to maintain the same premium perception in the mass market.
What Investors Should Track
Moving forward, the primary monitorables for investors will be how Honasa integrates these new operations. Specifically, the market will watch for the timeline of when Honasa Health launches its first B2C products and how the company plans to scale the Fluence Pharma brands without diluting their clinical reputation. Furthermore, investors should keep an eye on how much additional capital is deployed into the new subsidiary over the coming quarters and whether this expansion puts pressure on the company’s profit margins in the short term.